Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PRNP | P04156 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | PTGFR | P43088 | 7/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25269537 | 1.00 | L3MBTL1 (0.40) | L3MBTL1PRNPLTB4RDPP4PTGFR | |
| SCHEMBL31059229 | 0.91 | L3MBTL1 (0.41) | L3MBTL1PRNPLTB4RDPP4PTGFR | |
| SCHEMBL25259300 | 0.91 | L3MBTL1 (0.41) | L3MBTL1PRNPLTB4RDPP4PTGFR | |
| SCHEMBL25652551 | 0.84 | L3MBTL1 (0.46) | L3MBTL1PRNPLTB4RMAPTALDH1A1 | |
| SCHEMBL26565122 | 0.83 | CASR (0.32) | LTB4R | |
| SCHEMBL26564752 | 0.82 | L3MBTL1 (0.49) | L3MBTL1PRNPLTB4RMAPTALDH1A1 | |
| SCHEMBL26565119 | 0.82 | LTB4R (0.33) | L3MBTL1LTB4RMAPT | |
| SCHEMBL25652546 | 0.82 | L3MBTL1 (0.48) | L3MBTL1PRNPLTB4RMAPTALDH1A1 | |
| SCHEMBL30533423 | 0.81 | L3MBTL1 (0.43) | L3MBTL1PRNPLTB4RDPP4PTGFR | |
| SCHEMBL30533422 | 0.81 | L3MBTL1 (0.43) | L3MBTL1PRNPLTB4RDPP4PTGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504706-A | Macrocyclic compounds having farnesyl transferase inhibitory activity | 库拉肿瘤学公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20240287023-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | KURA ONCOLOGY INC (US) | 2024-08-29 | — | — | US | disclosed |
| CN-118339152-A | Macrocyclic compounds having farnesyl transferase inhibitory activity | 库拉肿瘤学公司 | 2024-07-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287023-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | FNTA, FDPS, GGPS1 | L3MBTL1 4194/4885PRNP 4290/4885LTB4R 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.